CJC-1295
Also known as: CJC-1295 DAC, Modified GRF (1-29) (no-DAC variant)
CJC-1295 is a synthetic growth-hormone-releasing hormone (GHRH) analogue studied in early research for its reported ability to increase growth hormone and IGF-1 levels. It is not approved for human use in Australia.
- Category
- Growth Hormone Secretagogue
- Reported half-life
- Reported to differ by variant, the DAC version is reported to last several days, while no-DAC Modified GRF (1-29) is reported to act over roughly 30 minutes (varies by study)
- Common forms
- Lyophilised powder for reconstitution, Injectable solution
- Research status
- Not approved for human use in Australia; investigated in early clinical and preclinical research only. No marketed human therapeutic product.
- Last updated
- 21 June 2026
Claimed effects
The following effects are reported or claimed by users and in early research. They are not established medical facts and many are not supported by large human trials.
- Reported to increase growth hormone and IGF-1 levels
- Claimed by users to support recovery, body composition and sleep
- Early research indicates the DAC version may extend the duration of effect
- Often discussed in combination with ghrelin-mimetics such as ipamorelin (reported synergy)
How it is reported to work
CJC-1295 is reported to act as an analogue of growth-hormone-releasing hormone (GHRH), prompting the pituitary gland to release more growth hormone, which in turn is reported to raise IGF-1. The "DAC" (Drug Affinity Complex) version is reported to bind to blood proteins to extend its duration, while the no-DAC "Modified GRF (1-29)" variant is reported to act over a shorter window. These mechanisms are based on early research and are not established in large human trials.
Background
CJC-1295 is a synthetic growth-hormone-releasing hormone (GHRH) analogue. It exists in two commonly discussed forms: a longer-acting “DAC” version and a shorter-acting no-DAC variant often called Modified GRF (1-29). It is frequently mentioned together with ipamorelin in online communities. This page is educational information, not medical advice, and the effects below are claimed and reported, not medically established.
What the research actually shows
CJC-1295 has been examined in early-stage research, where it is reported to raise growth hormone and IGF-1 levels. However, large, long-term human clinical trials confirming benefits and safety are not available. Early signals are hypothesis-generating, not proof of efficacy or safety.
| Variant | Reported duration | Notes |
|---|---|---|
| CJC-1295 DAC | Several days (reported) | Binds blood proteins |
| Modified GRF (1-29) | ~30 minutes (reported) | No-DAC, shorter window |
What people use it for (reported)
Online, people report using CJC-1295 in attempts to support recovery, body composition and sleep, sometimes in combination with ghrelin-mimetics. These are anecdotal reports, not validated clinical outcomes. Studies suggest a GHRH-analogue mechanism, but reported benefits should not be treated as established facts.
Things to be aware of
CJC-1295 is not approved for human use in Australia. Increasing growth hormone and IGF-1 can have unintended effects, and long-term consequences in humans are not well characterised. Grey-market product purity cannot be verified by consumers, a reason independent testing is discussed in this community.
If you have a health or recovery concern, the responsible step is to consult a qualified healthcare professional rather than self-experimenting. This article exists to help readers understand CJC-1295 and the evidence around it. It is not an endorsement, and it does not recommend obtaining, using or combining the compound.
Reported positives & side effects
Compiled from research and community reports. These are reported outcomes, not guarantees or medical advice, individual experiences vary widely.
Reported positives
- Reported to raise growth hormone and IGF-1 levels
- Users report improved recovery and body composition over time
- Reported to support deeper sleep
- The DAC version is reported to extend the duration of effect, reducing dosing frequency
- Reported to work well in combination with ghrelin-mimetics such as ipamorelin
Common side effects
- Injection-site reactions such as redness or itching
- Facial flushing or head-rush shortly after injection
- Water retention and puffiness
- Tingling or numbness in the hands
- Tiredness or drowsiness
Rare / serious side effects
- Carpal-tunnel-like symptoms from sustained growth-hormone elevation
- Changes in blood-sugar control or insulin sensitivity
- Allergic-type reactions
- Reactions attributed to impurities in unregulated grey-market product
Reported misuse & overdose risks
What has been reported to happen with overuse, excessive dosing, or long-term misuse of CJC-1295. Listed so you can make an informed decision, not to suggest any use is safe.
- Prolonged high-dose use, especially of the long-acting DAC version, is reported to keep growth hormone and IGF-1 elevated continuously, which removes the natural pulsatile pattern and is a frequently cited concern for suppressing normal regulation
- Sustained IGF-1 elevation from overuse is reported to raise theoretical concern about feeding abnormal tissue growth
- Overuse is reported to risk insulin resistance, higher blood sugar, fluid retention and joint pain consistent with growth-hormone excess
- The DAC version's long duration is reported to make overdosing harder to reverse, since effects cannot be quickly dialled back
- Unverified grey-market product is reported to risk contamination and incorrect dosing
Reported results timeline
Roughly how long people report it takes to notice effects. A general guide from reports, not a promise, and not advice. Sleep changes are often reported early, while recovery and body-composition effects are reported to build over several months.
First effects
Improved sleep within days
Noticeable change
Recovery and well-being ~4 weeks
Clear results
Body-composition changes ~12 weeks
Peak effect
Fuller effects reported ~16-24 weeks
Commonly reported dosing & protocol
Reported figures only, NOT a recommendation or dosing advice. These are numbers people report using, compiled for education so you can make an informed decision. We do not advise anyone to take CJC-1295. Many peptides are not approved for human use in Australia. Speak to a qualified healthcare professional.
| Route | Subcutaneous injection |
|---|---|
| Typical reported dose | Reported community figures of roughly 100 mcg per dose for the no-DAC / mod GRF form; the longer-acting DAC version is reported at roughly 1–2 mg per week |
| Frequency | No-DAC form reported as 1–3× daily (often with a ghrelin-mimetic); DAC form reported as roughly once or twice weekly |
| Cycle length | Reported cycles of about 8–12 weeks, then a break |
Reported reconstitution (mg → units)
Worked example only (no-DAC form): a 5 mg vial + 2 mL bacteriostatic water = 2.5 mg/mL. A 100 mcg (0.1 mg) dose ≈ 0.04 mL = 4 units on a U-100 insulin syringe.
Work out the units for your vial → CalculatorCommonly reported community patterns differ by variant: the no-DAC Modified GRF (1-29) is reported to be injected once or more daily timed with natural pulses, while the DAC version is reported to be dosed roughly once or twice weekly. Cycles of around 8 to 12 weeks with a break are commonly reported, often paired with ipamorelin. These are reported patterns only, not a recommendation, and CJC-1295 is not approved for human use.
Best used with / commonly stacked with
Combinations people report using together. Reported, not recommended, stacking can increase risks.
The classic reported pairing, a GHRH analogue plus a ghrelin-mimetic reported to produce a larger combined growth-hormone pulse
Reported as an alternative ghrelin-mimetic partner to boost the growth-hormone pulse
Reported alongside for recovery and injury support
Safety notes
CJC-1295 is not approved by the TGA for human use in Australia, and long-term human safety data is limited. Raising growth hormone and IGF-1 can carry risks, and grey-market product purity cannot be confirmed by consumers. Anyone considering it should first consult a qualified healthcare professional.